Nicholas Mitsakakis

Associate Scientist, CHEO Research Institute

Dr. Nicholas Mitsakakis is a Senior Biostatistician at the Clinical Research Unit and an Associate Scientist at the RI. He is also an adjunct faculty member of the Dalla Lana School of Public Health at the University of Toronto. Dr. Mitsakakis holds a PhD in Biostatistics from the University of Toronto and Master’s degrees in Artificial Intelligence (University of Edinburgh, UK) and Mathematics (University of Athens, Greece). He is an accredited professional statistician by the Statistical Society of Canada. His interests and expertise include clinical biostatistics, machine learning, health data science, and statistical methods for health economics and health related quality of life.

Additional Areas of Research: Biostatistics, Applied Machine Learning, Health Data Science

Research Projects

  1. Control-IQ Technology Positively Impacts Patient Reported Outcome Measures and Glycemic Control in Youth with Type 1 Diabetes in a Real-World Setting

    12/04/2023

    Initiation of Control-IQ technology in a real-world setting significantly reduced the impact of diabetes on daily life while simultaneously improving glycemic control

  2. Number of epilepsy surgeries has decreased despite an increase in pre-surgical evaluations at a tertiary pediatric epilepsy center in Ontario

    12/04/2023

    Despite an increasing trend in pre-surgical evaluation, there was a decreasing trend in the number of epilepsy surgery in the later period as there was a larger proportion of patients in whom the seizures could not be localized. Trends in presurgical evaluation and epilepsy surgery will continue to evolve with introduction of technologies such as stereo-EEG and minimally invasive laser therapy.

  3. Predicting the outcome of liver transplantation in patients with non-alcoholic steatohepatitis cirrhosis: The NASH LT risk-benefit calculator

    10/02/2023

    Our practically useable and validated risk score helps to identify and stratify candidates who will derive the most long-term benefit from LT for NASH cirrhosis.